Tenaya Therapeutics, Inc. is a U.S.-based biotechnology firm focused on unearthing, advancing, and providing novel treatments for various cardiovascular diseases. The company harnesses advanced scientific platforms, including cellular regeneration, gene therapy, and precision medicine, to develop its therapeutic candidates. Among its primary therapeutic initiatives is TN-201, an adeno-associated virus (AAV)-based gene therapy engineered to tackle genetic hypertrophic cardiomyopathy (gHCM) arising from haploinsufficient mutations in the myosin binding protein C3 (MYBPC3) gene. A prominent compound in its pipeline is TN-301, a small molecule histone deacetylase 6 inhibitor (HDAC6i) slated for use in both heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). Tenaya is also progressing TN-401, another AAV-based gene therapy aimed at genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) resulting from specific plakophilin 2 (PKP2) gene anomalies. Further, an AAV gene therapy is under development that seeks to introduce the dwarf open reading frame (DWORF) gene into cardiac tissue to address dilated cardiomyopathy (DCM). Rounding out its innovative portfolio, the 'Reprogramming program' employs an AAV-driven approach for cardiac regeneration, striving to replenish heart cells lost in patients who experience heart failure subsequent to a prior myocardial infarction. Founded in 2016, Tenaya operates from its base in South San Francisco, California.
